Iovance Biotherapeutics Inc (NAS:IOVA)
$ 9.4 0.28 (3.07%) Market Cap: 2.86 Bil Enterprise Value: 2.55 Bil PE Ratio: 0 PB Ratio: 3.70 GF Score: 39/100

Iovance Biotherapeutics Inc to Discuss Clinical Data for Lifileucel at ASCO Transcript

Jun 06, 2021 / 04:00PM GMT
Operator

Good day and thank you for standing by. Welcome to the Iovance Biotherapeutics ASCO Update Call. (Operator Instructions) As a reminder, this conference call might be recorded.

I would now like to turn the conference over to your host, Ms. Sara Pellegrino, Vice President, Investor and Public Relations.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you, operator. Good afternoon and thank you for joining our conference call to discuss the clinical data updates at ASCO 2021 for lifileucel in advanced melanoma.

For today's agenda, our incoming Interim President and CEO, Fred Vogt, will do a brief introduction and corporate update. Then the highlight of today's call will be the clinical data update presented by Dr. Omid Hamid, Chief of Research Immuno-Oncology at The Angeles Clinic and Research Institute. Dr. Hamid is recognized nationally and internationally as a key opinion leader in immuno-oncologic drug development and melanoma therapeutics, and we are very fortunate to have him join us today. Our Chief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot